

From: [Dan Forche](#)
To: [GABRIEL BIEN-WILLNER](#); [MOLDX](#)
Cc: [Troy Bremer](#); [Andy Wade](#); [Edwin Hendrick](#)
Subject: [EXTERNAL] DCISionRT Formal Tech Assessment - Submission - Files 1 - 6.0 - Email One of Six
Date: Monday, June 1, 2020 9:23:08 PM
Attachments: [image007.png](#)
[image008.png](#)
[image009.png](#)
[image010.png](#)
[image011.png](#)
[image012.png](#)

WARNING: This is an external email that originated outside of our email system. DO NOT CLICK links or open attachments unless you recognize the sender and know that the content is safe!

Dear Dr. Bien-Willner and MoldX Team,

We are very excited to submit our official Technology Assessment for DCISionRT to MoldX. This has been a collaborative process with the MoldX team over the last two years and I want to thank everyone for their efforts and guidance.

We are extremely passionate about women's health and believe DCISionRT provides personalized precision medicine to each patient and their physician for better clinical outcomes and treatment decisions. The non-linear AI bio-algorithmic test is the first DCIS test that integrates biology with clinicopathologic factors to provide a quantified and clinically significant risk assessment for DCIS patients. The DCISionRT test is having a positive impact to the management and treatment of DCIS patients throughout the US as we have provided test results to over 5,000 patients and over 700 physicians. Approximately one third of those patients were in the growing Medicare population.

I will be sending a series of **six** emails which will provide all of the technology assessment files. The files range in order from 1.00 – 9.00. We will also be sending hard copy binders that will provide an organized and easy way to access the documents. I have also included the table of contents in this body of this email and as an attachment. Attached in this first email are files 1.00 – 7.30.

Email #1

LCD Check List – 1.0

Table of Contents – 2.0

Executive Summary – 3.0

Tech Summary Sheets – 4.0


Dossier Summary – 5.0

TRF and Sample Reports – 6.0

Thank you again for your support and consideration.

Best regards,

Dan



Daniel Forche

President and CEO

PreludeDx | www.preludedx.com

Office: 888-211-DCIS (3247)

Mobile: [949-300-7631](tel:949-300-7631)

Email: dforche@preludedx.com

